Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $12 price target on the stock.
November 28, 2023 | 5:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Coherus BioSciences with a $12 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating by a Truist Securities analyst, along with the maintenance of a $12 price target, suggests a strong vote of confidence in Coherus BioSciences. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100